Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lexaria Bioscience (LEXX) EBT Margin (2017 - 2026)

Lexaria Bioscience's EBT Margin history spans 10 years, with the latest figure at 7250.67% for Q1 2026.

  • On a quarterly basis, EBT Margin fell 566963.0% to 7250.67% in Q1 2026 year-over-year; TTM through Feb 2026 was 2570.59%, a 78692.0% decrease, with the full-year FY2025 number at 1682.58%, down 44651.0% from a year prior.
  • EBT Margin hit 7250.67% in Q1 2026 for Lexaria Bioscience, down from 1543.55% in the prior quarter.
  • Over the last five years, EBT Margin for LEXX hit a ceiling of 460.69% in Q1 2024 and a floor of 7250.67% in Q1 2026.
  • Historically, EBT Margin has averaged 2663.89% across 5 years, with a median of 2115.1% in 2024.
  • Biggest five-year swings in EBT Margin: soared 1269960bps in 2022 and later crashed -566963bps in 2026.
  • Tracing LEXX's EBT Margin over 5 years: stood at 1734.71% in 2022, then soared by 57bps to 748.17% in 2023, then crashed by -96bps to 1462.95% in 2024, then dropped by -6bps to 1543.55% in 2025, then plummeted by -370bps to 7250.67% in 2026.
  • Business Quant data shows EBT Margin for LEXX at 7250.67% in Q1 2026, 1543.55% in Q3 2025, and 2155.31% in Q2 2025.